BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8278024)

  • 1. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
    Lane RJ; McLean KA; Moss J; Woodrow DF
    Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis in AZT myopathy.
    Chalmers AC; Greco CM; Miller RG
    Neurology; 1991 Aug; 41(8):1181-4. PubMed ID: 1714057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.
    Pezeshkpour G; Illa I; Dalakas MC
    Hum Pathol; 1991 Dec; 22(12):1281-8. PubMed ID: 1748434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV or zidovudine myopathy?
    Gherardi R; Chariot P
    Neurology; 1994 Feb; 44(2):361-2; author reply 362-4. PubMed ID: 8309597
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV or zidovudine myopathy?
    Dalakas M
    Neurology; 1994 Feb; 44(2):360-1; author reply 362-4. PubMed ID: 8309594
    [No Abstract]   [Full Text] [Related]  

  • 6. 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients.
    Weissman JD; Constantinitis I; Hudgins P; Wallace DC
    Neurology; 1992 Mar; 42(3 Pt 1):619-23. PubMed ID: 1549225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
    Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
    Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.
    Schröder JM; Bertram M; Schnabel R; Pfaff U
    Acta Neuropathol; 1992; 85(1):39-47. PubMed ID: 1285495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial myopathy caused by long-term zidovudine therapy.
    Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
    N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
    Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R
    Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cytochrome c oxidase subunits encoded by mitochondrial or nuclear DNA in the muscle of patients with zidovudine myopathy.
    Chariot P; Bonne G; Authier FJ; Marsac C; Gherardi R
    J Neurol Sci; 1994 Sep; 125(2):190-3. PubMed ID: 7807166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV or zidovudine myopathy?
    Grau JM; Casademont J
    Neurology; 1994 Feb; 44(2):361; author reply 362-4. PubMed ID: 8309595
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers.
    Gherardi RK; Florea-Strat A; Fromont G; Poron F; Sabourin JC; Authier J
    Ann Neurol; 1994 Nov; 36(5):752-8. PubMed ID: 7979221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal muscle involvement in HIV-infected patients.
    Gherardi RK
    Neuropathol Appl Neurobiol; 1994 Jun; 20(3):232-7. PubMed ID: 7936072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy.
    Morgello S; Wolfe D; Godfrey E; Feinstein R; Tagliati M; Simpson DM
    Acta Neuropathol; 1995; 90(4):366-74. PubMed ID: 8546027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection.
    Chen SC; Barker SM; Mitchell DH; Stevens SM; O'Neill P; Cunningham AL
    Pathology; 1992 Apr; 24(2):109-11. PubMed ID: 1641255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine-associated myopathy.
    Paradis J; Calis KA
    Am J Hosp Pharm; 1994 Dec; 51(24):3026-8. PubMed ID: 7856620
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy.
    Chariot P; Monnet I; Gherardi R
    Ann Neurol; 1993 Oct; 34(4):561-5. PubMed ID: 8215243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and pathogenesis of myositis in human immunodeficiency virus infection--distinction from azidothymidine-induced myopathy.
    Espinoza LR; Aguilar JL; Espinoza CG; Gresh J; Jara J; Silveira LH; Martinez-Osuna P; Seleznick M
    Rheum Dis Clin North Am; 1991 Feb; 17(1):117-29. PubMed ID: 2041882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?
    Simpson DM; Citak KA; Godfrey E; Godbold J; Wolfe DE
    Neurology; 1993 May; 43(5):971-6. PubMed ID: 8492955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.